NASDAQ:ANEB Anebulo Pharmaceuticals Q3 2025 Earnings Report $0.46 +0.00 (+0.54%) As of 03:05 PM Eastern ProfileEarnings HistoryForecast Anebulo Pharmaceuticals EPS ResultsActual EPS-$0.04Consensus EPS -$0.05Beat/MissBeat by +$0.01One Year Ago EPSN/AAnebulo Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnebulo Pharmaceuticals Announcement DetailsQuarterQ3 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time4:00PM ETUpcoming EarningsAnebulo Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anebulo Pharmaceuticals Earnings HeadlinesAnebulo Pharmaceuticals (ANEB) Projected to Post Earnings on ThursdayMay 6 at 3:57 AM | americanbankingnews.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesFebruary 13, 2026 | finance.yahoo.comElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.May 6 at 1:00 AM | InvestorPlace (Ad)Anebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plansFebruary 6, 2026 | in.investing.comAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECFebruary 6, 2026 | finance.yahoo.comAnebulo Pharmaceuticals Announces Final Results of Tender OfferJanuary 29, 2026 | finance.yahoo.comSee More Anebulo Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email. Email Address About Anebulo PharmaceuticalsAnebulo Pharmaceuticals (NASDAQ:ANEB) (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments. The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief. Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.View Anebulo Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageDigitalOcean’s AI Surge: How Far Can This Rally Go?Years in the Making, AMD’s Upside Movement Has Just BegunCapital One’s Big Bet Faces Rising Credit RiskWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootHow Williams Companies Is Cashing in on the AI Power Boom Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
